Polymorphs of N-methyl-N-(3-3-{2-thienylcarbonyl]-pyrazol -[1,5-alpha]-pyrimidin-7-yl}phenyl)a cetamide and compositions and methods related thereton

A technology of acetamide and polymorphs, applied in the field of polymorphs of N-methyl-N-acetamide, can solve problems such as limiting effective use

Inactive Publication Date: 2005-04-27
NEUROCRINE BIOSCI INC
View PDF11 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] However, like the use of barbiturates, benzodiazepines have some side effects that limit their effective use in certain patient populations

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Polymorphs of N-methyl-N-(3-3-{2-thienylcarbonyl]-pyrazol -[1,5-alpha]-pyrimidin-7-yl}phenyl)a cetamide and compositions and methods related thereton
  • Polymorphs of N-methyl-N-(3-3-{2-thienylcarbonyl]-pyrazol -[1,5-alpha]-pyrimidin-7-yl}phenyl)a cetamide and compositions and methods related thereton
  • Polymorphs of N-methyl-N-(3-3-{2-thienylcarbonyl]-pyrazol -[1,5-alpha]-pyrimidin-7-yl}phenyl)a cetamide and compositions and methods related thereton

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0133] Synthesis of compound 1

[0134]This example illustrates the synthesis of Compound 1 by known techniques, resulting in Compound 1 being a mixture of the Form I polymorph and the Form II polymorph, according to figure 1 confirmed by the DSC thermogram.

[0135]

[0136] β-Dimethylamino-1-(2-thienyl)-2-propen-1-one (3).

[0137] A mixture of 2-acetylthiophene 2 (20.0 g, 159 mmol) and dimethylformamide dimethyl acetal (39 g, 327 mmol) was refluxed under nitrogen for three hours. The reaction mixture was cooled and concentrated to give a dark orange-red solid. The solid was collected by filtration and triturated with a solution of dichloromethane and ether (1:10, 200 mL). The resulting compound 3 was an orange solid (22.0 g, 121 mmol, 76%). GC / MS, m / z=181 at tR=11.83 min (100%). LC / MS, [M+H]=182.

[0138] 5-(2-Thienyl)isoxazole (4).

[0139] A mixture of compound 3 (18.1 g, 100 mmol) and hydroxylamine hydrochloride (7.0 g, 101 mmol) was refluxed in 100 mL of...

Embodiment 2

[0152] Synthesis of Substantially Pure Form I Polymorph

[0153] 100 mL of acetone was added to 1.5 g of compound 1 prepared as in Example 1. Heat to reflux until the solution is homogeneous. The solution was quickly passed through a molten glass funnel. The solution was then slowly cooled to room temperature, which took approximately 1 hour. The mixture was further cooled to 5°C with an ice bath. The solid formed was collected by filtration and washed with 10 mL of cold acetone to yield 0.4 g of the Form I polymorph. The mother liquor was concentrated in vacuo to approximately 20 mL. The solution was cooled to 5°C. The solid was collected by filtration and washed with 10 mL of cold acetone to yield an additional 0.5 g of Form I polymorph.

Embodiment 3

[0155] basically pure II Synthesis of polymorphs

[0156] 75 mL of methanol was added to 1.4 g of compound 1 prepared as in Example 1. Heat to reflux until the solution is homogeneous. The solution was quickly passed through a molten glass funnel. The solution was then slowly cooled to room temperature, which took approximately 1 hour. The mixture was further cooled to 5°C with an ice bath. The solid formed was collected by filtration and washed with 10 mL of cold methanol to yield 0.5 g of the Form II polymorph. The mother liquor was concentrated in vacuo to approximately 10 mL. The solution was cooled to 5°C. The solid was collected by filtration and washed with 10 mL of cold methanol to yield an additional 0.4 g of Form II polymorph.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Polymorphs of N-methyl-N-(3-ä3-Ä2-thienylcarbonylÜ-pyrazol-Ä1,5- alpha Ü-pyrimidin-7-ylüphenyl)acetamide (Compound (1)), and use of the same as a sedative-hypnotic, anxiolytic, anticonvulsant, and skeletal muscle relaxant agent. Processes for making the same, as well as related compositions and methods are also disclosed, particularly with regard to treatment of insomnia. A polymorph Form I possessing exception physical and heat stability is provided. A polymorph Form II, is also provided.

Description

Field of Invention [0001] The present invention relates to polymorphic forms of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazole-[1,5-α]-pyrimidin-7-yl}phenyl)acetamide The substance is active in many indications, and is particularly effective for the treatment of insomnia, and also relates to a related method, a composition containing the substance and a preparation method. Background of the Invention [0002] The term "insomnia" is used to describe all states of discomfort associated with a patient's sleep deprivation or non-resting sleep sensations (Dement, International Pharmacopsychiatry 17:3-38, 1982). Insomnia is the most frequent disorder reported to be present in approximately 32% of adults surveyed in Los Angeles (Bixler et al., Amer. Journal of Psychiatry 136:1257-1262, 1979 ), about 13% of the population surveyed in San Marino, Italy, suffered from insomnia (Lugaresi et al., Psychiatric Annals 17:446-453, 1987). At least 45% of the surveyed ad...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K9/20A61K9/48A61K31/505A61K31/519A61P21/02A61P25/08A61P25/20A61P25/22C07D487/02C07D487/04
CPCC07D487/04A61P21/00A61P21/02A61P25/08A61P25/20A61P25/22
Inventor W·J·瑟勒P·B·欧达尼尔
Owner NEUROCRINE BIOSCI INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap